| Description | Atpenin A5 is a potent and highly specific complex II inhibitor (IC50 ~10 nM). Atpenin A5 is also an effective mKATP channel agonist and cardioprotective agent[1]. |
| In vitro | Atpenin A5 shows the inhibition profile for submitochondrial particles (SMPs), mitochondria, and cardiomyocytes, with IC50 values of 8.3 nM, 9.3 nM, and 8.5 nM, respectively. Atpenin A5 (AA5) is a potent and specific complex II inhibitor. Atpenin A5 (1 nM) also activates the mKATP channel and protects against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes[1]. |
| In vivo | Atpenin A5 is a potent inhibitor of succinate dehydrogenase (SDH). SDH inhibition by Atpenin A5 promotes cardiomyocyte mitosis and regeneration in the postnatal heart after myocardial infarction (MI). Atpenin A5-injected (100 μg/kg) mice demonstrated myocardial thickness at the infarct zone and a significant reduction in scar size compared with controls[2]. |
| molecular weight | 366.24 |
| Molecular formula | C15H21Cl2NO5 |
| CAS | 119509-24-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (273.04 mM), Sonication is recommended. |